Vivoryon Therapeutics NV banner

Vivoryon Therapeutics NV
AEX:VVY

Watchlist Manager
Vivoryon Therapeutics NV Logo
Vivoryon Therapeutics NV
AEX:VVY
Watchlist
Price: 1.275 EUR 2% Market Closed
Market Cap: €37.8m

Wall St Price Targets

VVY Price Targets Summary
Vivoryon Therapeutics NV

Wall Street analysts forecast VVY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VVY is 5.95 EUR with a low forecast of 5.05 EUR and a high forecast of 7.875 EUR.

Lowest Forecast
Price Target
5.05 EUR
296% Upside
Average Forecast
Price Target
5.95 EUR
367% Upside
Highest Forecast
Price Target
7.875 EUR
518% Upside
Vivoryon Therapeutics NV Competitors:
Price Targets
ACAD
ACADIA Pharmaceuticals Inc
49% Upside
CALM
Cal-Maine Foods Inc
12% Upside
AYTU
Aytu Biopharma Inc
319% Upside
VYNE
Vyne Therapeutics Inc
204% Upside

Revenue
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
4%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
4%
Average Beat

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-52%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-52%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is VVY's stock price target?
Price Target
5.95 EUR

According to Wall Street analysts, the average 1-year price target for VVY is 5.95 EUR with a low forecast of 5.05 EUR and a high forecast of 7.875 EUR.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett